Published in Springer Semin Immunopathol on November 08, 2006
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med (2013) 3.83
Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo. Nat Med (2014) 2.72
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood (2010) 2.06
Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. Blood (2008) 1.55
Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice. J Clin Invest (2011) 1.50
CD19: a promising B cell target for rheumatoid arthritis. Nat Rev Rheumatol (2009) 1.24
Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties. J Immunol (2013) 1.18
Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity. J Immunol (2014) 1.13
B cell depletion with anti-CD79 mAbs ameliorates autoimmune disease in MRL/lpr mice. J Immunol (2008) 1.11
Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40. Br J Cancer (2008) 1.00
Monocytes mediate shaving of B-cell-bound anti-CD20 antibodies. Immunology (2011) 0.95
The role of myeloid cells in cancer therapies. Nat Rev Cancer (2016) 0.92
Antigenic modulation and rituximab resistance. Semin Hematol (2010) 0.92
Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies? Oncoimmunology (2012) 0.91
A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies. J Hematol Oncol (2014) 0.85
Galectin-1 drives lymphoma CD20 immunotherapy resistance: validation of a preclinical system to identify resistance mechanisms. Blood (2016) 0.82
Interleukin-21 enhances rituximab activity in a cynomolgus monkey model of B cell depletion and in mouse B cell lymphoma models. PLoS One (2013) 0.81
B cell modulation in rheumatology. Curr Opin Pharmacol (2007) 0.77
Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods (1994) 13.53
Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med (2000) 13.24
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood (2002) 8.76
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol (1998) 8.40
Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet (1998) 8.20
FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell (1994) 7.66
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol (2003) 6.77
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood (1994) 6.47
Fcgamma receptors: old friends and new family members. Immunity (2006) 5.60
IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood (1997) 4.97
Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science (2001) 4.62
Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. Proc Natl Acad Sci U S A (1995) 4.33
IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol (1997) 4.32
FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity (2005) 4.22
Role of colony stimulating factor-1 in the establishment and regulation of tissue macrophages during postnatal development of the mouse. Development (1994) 3.86
The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med (2004) 3.56
Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood (1988) 3.30
Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol (2005) 3.00
Roles of Fc receptors in autoimmunity. Nat Rev Immunol (2002) 2.96
Impaired IgG-dependent anaphylaxis and Arthus reaction in Fc gamma RIII (CD16) deficient mice. Immunity (1996) 2.96
Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood (1998) 2.83
IgG2a restriction of murine antibodies elicited by viral infections. J Exp Med (1987) 2.81
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene (2003) 2.80
The need for IgG2c specific antiserum when isotyping antibodies from C57BL/6 and NOD mice. J Immunol Methods (1998) 2.78
Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood (1984) 2.74
The half-lives of serum immunoglobulins in adult mice. Eur J Immunol (1988) 2.73
Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity (1995) 2.69
Activation of mouse complement by different classes of mouse antibody. Immunology (1979) 2.68
Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood (2000) 2.64
Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol (2003) 2.62
An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum (2002) 2.54
CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood (2001) 2.53
Lymphocyte subsets in the blood: a diagnostic window on the lymphoid system? Immunol Today (1990) 2.50
Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood (1994) 2.48
Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) (2001) 2.45
Phenotypic difference of normal plasma cells from mature myeloma cells. Blood (1993) 2.35
FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. Immunity (2002) 2.31
CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today (1994) 2.25
Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol (1998) 2.21
Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity (2003) 2.20
Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood (1998) 2.17
The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J Immunol (2005) 2.16
CD22 regulates B lymphocyte function in vivo through both ligand-dependent and ligand-independent mechanisms. Nat Immunol (2004) 2.16
IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells. Proc Natl Acad Sci U S A (1982) 2.15
Activation of mouse complement by monoclonal mouse antibodies. Eur J Immunol (1981) 2.11
Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood (2003) 2.04
The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum (2003) 2.02
Mouse CD20 expression and function. Int Immunol (2004) 2.02
The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Immunity (1997) 2.00
Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med (1993) 1.95
Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum (2003) 1.94
CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity. J Immunol (1996) 1.90
Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood (2002) 1.87
Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol (2001) 1.86
Immunoglobulin G-mediated inflammatory responses develop normally in complement-deficient mice. J Exp Med (1996) 1.83
More is not necessarily better: prozone-like effects in passive immunization with IgG. J Immunol (2003) 1.81
Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J Exp Med (2006) 1.80
Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. J Cell Biol (1993) 1.80
Pathogenic roles of B cells in human autoimmunity; insights from the clinic. Immunity (2004) 1.79
Isolation of cDNAs encoding the CD19 antigen of human and mouse B lymphocytes. A new member of the immunoglobulin superfamily. J Immunol (1989) 1.78
Identification and characterization of plasma cells in normal human bone marrow by high-resolution flow cytometry. Blood (1990) 1.76
Opsonization of Cryptococcus neoformans by a family of isotype-switch variant antibodies specific for the capsular polysaccharide. Infect Immun (1990) 1.72
Mechanisms of antibody-mediated protection against lymphocytic choriomeningitis virus infection: mother-to-baby transfer of humoral protection. J Virol (1992) 1.66
B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol (2006) 1.64
Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood (2003) 1.61
CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk Lymphoma (1995) 1.61
Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother (2000) 1.60
Tissue-specific expression of the human CD19 gene in transgenic mice inhibits antigen-independent B-lymphocyte development. Mol Cell Biol (1994) 1.54
New prospects for autoimmune disease therapy: B cells on deathwatch. Arthritis Rheum (2006) 1.51
Murine IgG1 complexes trigger immune effector functions predominantly via Fc gamma RIII (CD16). J Immunol (1998) 1.49
Identification of the mouse IgG3 receptor: implications for antibody effector function at the interface between innate and adaptive immunity. J Immunol (1998) 1.45
Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Trans (1997) 1.45
CD19 expression levels regulate B lymphocyte development: human CD19 restores normal function in mice lacking endogenous CD19. J Immunol (1997) 1.44
Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol (2000) 1.44
Inflammation in autoimmunity: receptors for IgG revisited. Trends Immunol (2001) 1.41
FcgammaRIII (CD16)-deficient mice show IgG isotype-dependent protection to experimental autoimmune hemolytic anemia. Blood (1998) 1.40
Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm (1997) 1.40
Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants. J Immunol (1986) 1.40
Complement activation selectively potentiates the pathogenicity of the IgG2b and IgG3 isotypes of a high affinity anti-erythrocyte autoantibody. J Exp Med (2002) 1.39
Structural organization of the human MS4A gene cluster on Chromosome 11q12. Immunogenetics (2001) 1.38
CD22 ligand binding regulates normal and malignant B lymphocyte survival in vivo. J Immunol (2006) 1.37
CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction. Adv Immunol (2005) 1.36
Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood (2002) 1.34
Influence of antibody isotype on passive serotherapy of lymphoma. J Immunol (1985) 1.33
Identification of a CD20-, FcepsilonRIbeta-, and HTm4-related gene family: sixteen new MS4A family members expressed in human and mouse. Genomics (2001) 1.25
Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4. J Immunol (2000) 1.23
Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity. J Immunol (1987) 1.23
Fc receptor homologs: newest members of a remarkably diverse Fc receptor gene family. Immunol Rev (2002) 1.18
An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab. Blood (2002) 1.17
Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J Immunother (2001) 1.15
Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. Proc Natl Acad Sci U S A (2005) 1.15
Monoclonal antibody-based therapies of leukemia and lymphoma. Blood (1992) 1.15
Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways. Cancer Res (2000) 1.14
Anti-CD19 inhibits the growth of human B-cell tumor lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrest. Blood (1994) 1.13
Immunotherapy of Non-Hodgkin's lymphomas. Hematology Am Soc Hematol Educ Program (2001) 1.12
High pathogenic potential of low-affinity autoantibodies in experimental autoimmune hemolytic anemia. J Exp Med (1999) 1.09
Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J Exp Med (2006) 1.80
Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. Blood (2008) 1.55
FDG-PET imaging in primary bilateral adrenal lymphoma: a case report and review of the literature. Clin Nucl Med (2005) 1.38
18F-FDG PET in evaluation of adrenal lesions in patients with lung cancer. J Nucl Med (2004) 1.31
Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression. Mol Cancer Ther (2008) 1.13
Late developmental stage-specific role of tryptophan hydroxylase 1 in brain serotonin levels. J Neurosci (2006) 1.13
Osteoclast fusion and regulation by RANKL-dependent and independent factors. World J Orthop (2012) 1.11
18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas. J Nucl Med (2004) 1.08
F-18 FDG positron emission tomography in non-Hodgkin lymphoma of the breast. Clin Nucl Med (2005) 1.02
2-Deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography in characterization of solid renal masses. Mol Imaging Biol (2006) 0.98
Noncanonical NF-κB signaling regulates hematopoietic stem cell self-renewal and microenvironment interactions. Stem Cells (2012) 0.95
Small urine leak after renal transplantation: detection by delayed 99mTc-DTPA renography--a case report. J Nucl Med Technol (2005) 0.91
CD3 and immunoglobulin G Fc receptor regulate cerebellar functions. Mol Cell Biol (2007) 0.89
Gossypol, a phytochemical with BH3-mimetic property, sensitizes cultured thoracic cancer cells to Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J Thorac Cardiovasc Surg (2006) 0.89
Chloroquine reduces osteoclastogenesis in murine osteoporosis by preventing TRAF3 degradation. J Clin Invest (2013) 0.88
Differential diagnostic value of single-photon emission computed tomography/spiral computed tomography with Tc-99m-methylene diphosphonate in patients with spinal lesions. Nucl Med Commun (2011) 0.87
Genetic dissection of the effects of stimulatory and inhibitory IgG Fc receptors on murine lupus. J Immunol (2006) 0.87
Requirement of tryptophan hydroxylase during development for maturation of sensorimotor gating. J Mol Biol (2006) 0.87
Transgene-mediated hyper-expression of IL-5 inhibits autoimmune disease but increases the risk of B cell chronic lymphocytic leukemia in a model of murine lupus. Eur J Immunol (2004) 0.85
Demonstration of increased FDG activity in Rosai-Dorfman disease on positron emission tomography. Clin Nucl Med (2004) 0.84
Diffuse FDG uptake in the lungs in aspiration pneumonia on positron emission tomographic imaging. Clin Nucl Med (2004) 0.81
Role of 18F-FDG PET/CT Imaging in Intrahepatic Cholangiocarcinoma. Clin Nucl Med (2016) 0.80
Visual and semi-quantitative analyses of dual-phase breast-specific gamma imaging with Tc-99m-sestamibi in detecting primary breast cancer. Ann Nucl Med (2013) 0.79
Diffuse bone marrow accumulation of FDG in a patient with chronic myeloid leukemia mimics hematopoietic cytokine-mediated FDG uptake on positron emission tomography. Clin Nucl Med (2004) 0.79
SPECT/CT imaging of patella metastasis from a squamous carcinoma of the lung. Clin Nucl Med (2013) 0.79
Genetic dissection of anxiety in autoimmune disease. Hum Mol Genet (2003) 0.77
Chronic cholecystitis detected by FDG-PET. Clin Nucl Med (2004) 0.76
Fibronectin splice variation in human knee cartilage, meniscus and synovial membrane: observations in osteoarthritic knee. J Orthop Res (2015) 0.76
Primary pulmonary osteosarcoma: PET/CT and SPECT/CT findings. Clin Nucl Med (2011) 0.75
Added value of SPECT/spiral CT versus SPECT or CT alone in diagnosing solitary skeletal lesions. Nuklearmedizin (2017) 0.75
Adenosquamous Carcinoma of the Pancreas Demonstrated on 18F-FDG PET/CT Imaging. Clin Nucl Med (2017) 0.75
Follow-up FDG PET in the evaluation of unexplained focal activity in the abdomen. Clin Nucl Med (2008) 0.75
Diagnostic value of 99mTc-MDP SPECT/spiral CT combined with three-phase bone scintigraphy in assessing suspected bone tumors in patients with no malignant history. Nucl Med Commun (2015) 0.75
Added value of SPECT/spiral CT versus SPECT in diagnosing solitary spinal lesions in patients with extraskeletal malignancies. Nucl Med Commun (2013) 0.75
Optimized image acquisition parameters for imaging radioactive iodine-125 seed implantation for cancer treatment. Hell J Nucl Med (2015) 0.75